Program Type: Midwest CEPAC

Amyotrophic Lateral Sclerosis (ALS)

Aug 2022 | Assessment

Interventions of Interest: AMX0035 (Amylyx Pharmaceuticals, Inc.) oral edaravone (Mitsubishi Tanabe Pharma Development America, Inc.) Amyotrophic lateral sclerosis (ALS) is a rare, progressive, neurodegenerative disease characterized by loss of motor neurons in the brain and spinal cord. ALS often begins with localized weakness that will progress to involve most muscles. People with ALS typically die […]

COVID-19

Apr 2022 | Assessment

Interventions of Interest: molnupiravir (Merck) PF-07321332/ritonavir (Paxlovid™, Pfizer) fluvoxamine (Investigator initiated) We have deemed this a “special assessment” since this is an early snapshot of emerging agents in the COVID-19 pipeline. Each company has evolving timelines around data availability and potential approvals. Independent appraisal committee voted 11-2 that the evidence is not adequate to demonstrate […]

Asthma

Nov 2021 | Assessment

Interventions of Interest: Tezepelumab (Tezpire, Amgen/AstraZeneca) ICER’s Evidence Report Findings: Tezepelumab reduces asthma exacerbations, but there is uncertainty about long-term safety as with all new biologic therapies; tezepelumab would achieve common thresholds for cost-effectiveness if priced between $9,000 – $12,100 per year. Recommendations for fair access include ensuring that all biologic options be available for […]

Multiple Myeloma

Apr 2021 | Assessment

Interventions of Interest: idecabtagene vicleucel (Abecma®, Bristol-Myers Squibb, bluebird bio) ciltacabtagene autoleucel (Carvykti™, Johnson & Johnson, Legend Biotech Corp) Belantamab mafodotin (Blenrep™, GlaxoSmithKline) The Midwest CEPAC unanimously determined the evidence is adequate to demonstrate that CAR-T treatments ide-cel and cilta-cel both provide a net health benefit when compared to usual care; despite these benefits, for […]